Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 16
---
processes are executed by the Company’s management team. The Company believes that division of responsibilities enables the Company
to address risks most effectively.

Role of the Board in Human Capital Oversight

The Company places significant emphasis
on the recruitment, development, and retention of its employees who include award-winning scientists dedicated to advancing scientific
discovery from bench to bedside. We employ 62 employees at the time of this filing, 25 employed by bioAffinity Technologies and 37 employed
by our subsidiary laboratory, Precision Pathology Laboratory Services (“PPLS”). Of our seven employees
engaged in research and development, all of whom are employed full-time, three hold Ph.Ds. in biology or medicinal chemistry.

Our Chief Science Officer, William Bauta,
Ph.D., was the Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was
responsible for the discovery, development, and FDA approval of therapeutics in the companies’ pipelines, and Manager of
Medicinal and Process Chemistry at Southwest Research Institute. Our Chief Medical Officer, Gordon Downie, M.D., Ph.D., is an interventional
pulmonologist who most recently served as Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical
Center in Texas. He has led FDA-approved research programs, and served in national leadership roles with the American College of Chest
Physicians. Business development is led by our Chief Operating Officer, Xavier Reveles, who has 25 years of experience as a clinical
geneticist skilled in the creation and management of CLIA clinical laboratories, coding, and CPT reimbursement valuations. Mr. Reveles
is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics who has successfully launched
multiple diagnostics and commercial laboratories. We have attracted experienced salespeople with a proven record in the pulmonary field.
In November 2023, we hired our Vice President of Sales who has more than 15 years of experience in medical sales and marketing,
most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division. Our
innovative and collaborative culture is in part responsible for our ability to attract and retain highly skilled professionals seeking
professional advancement. Outside partnerships and collaborations that advance business and scientific research are encouraged, allowing
us to multiply workforce efforts without expending significant capital.

The Board, led by the Compensation Committee, oversees
employee compensation and incentivization programs. The Company